Search
On December 17, 2025, Harbour BioMed-B (02142) disclosed that it had entered into a multi-year, global strategic collaboration and license agreement with Bristol-Myers Squibb. The aim is to jointly embark on the discovery and development of next-generation multispecific antibodies. Under the terms of this agreement, Harbour BioMed will take charge of driving forward and expediting the discovery process of multispecific antibodies. In return for its efforts, it will receive an upfront payment of US$90 million. Moreover, should Bristol-Myers Squibb decide to advance all potential projects, Harbour BioMed stands to gain development and commercial milestone payments of up to US$1.035 billion. Additionally, it will be entitled to tiered royalties.
-
C114 Communication Network -
Communication Home
